Approved in the U.S. for adults with myelofibrosis with a platelet count below 50 x 109/L.

Learn More

An Ongoing Phase 3 Trial

Pacritinib is being evaluated compared to physicians’ choice therapy for the treatment of patients with myelofibrosis with severe thrombocytopenia.

Measuring Success in Terms of Our Impact on Patients

Join our team to advance new medicines that make a difference to patients.
See Open Positions